Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomised, Placebo-controlled, Parallel Group, Phase IIa Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 765423 Administered Intravenously With or Without Standard of Care in Patients With Idiopathic Pulmonary Fibrosis

NCT07036523 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07036523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07036523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomised, Placebo-controlled, Parallel Group, Phase IIa Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 765423 Administered Intravenously With or Without Standard of Care in Patients With Idiopathic Pulmonary Fibrosis
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 13, 2025
Completion date
June 22, 2027
Enrollment
81 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis